Latest Pharma Insights
GMP Violations Snag Rohto Eye Drop Plant In Vietnam, OTC Biologics Sales Trip Malaysian Firm
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Samsung Biologics Strike Threat Puts Client Confidence In Focus
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Biobeat Says Chest Patch Could Provide Alternative To Cuff-Based BP Monitoring
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Samsung Biologics Strike Threat Puts Client Confidence In Focus
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Major global CDMO Samsung Biologics and labor union set to open new new talks designed to resolve pay dispute.
Scrip - October 28, 2026
Biobeat Says Chest Patch Could Provide Alternative To Cuff-Based BP Monitoring
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
Biobeat says interim data from its 600-patient trial support its FDA-cleared chest patch as a more comfortable alternative to cuff-based 24-hour blood pressure monitoring. The 2025 AHA/ACC hypertension guideline still advises against cuffless devices for diagnosis.
Medtech Insight - October 28, 2026
GMP Violations Snag Rohto Eye Drop Plant In Vietnam, OTC Biologics Sales Trip Malaysian Firm
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Japanese firm Rohto Pharmaceutical warned about GMP deficiencies at its plant in Ho Chi Minh, Vietnam, which led to recall started in July of all lots of its Rohto brand. FDA’s CBER warned Beaute Bounty in Kuala Lumpur after reviews of its website determined it was selling unlicensed biological prod
HBW Insight - October 28, 2026
Teva Seals Trump Administration API Deal With MFN Pricing Pledge
Teva joins US efforts to strengthen the domestic supply chain, as it finalizes a governmental deal to donate API for key products, as well as pricing commitments for Medicaid and MFN policies for applicable future innovative launches.
Generics Bulletin - October 27, 2026
Teva joins US efforts to strengthen the domestic supply chain, as it finalizes a governmental deal to donate API for key products, as well as pricing commitments for Medicaid and MFN policies for applicable future innovative launches.
Generics Bulletin - October 27, 2026
Cosette Pharmaceuticals Gets FDA Nod For Liquid Oral Formulation Of Evoxac
As eight generic companies continue to compete for market share of Evoxac capsules, Cosette is now listed in the Orange Book as the only approved provider of a liquid oral formulation, following approval through the 505(b)(2) pathway.
Generics Bulletin - October 27, 2026
As eight generic companies continue to compete for market share of Evoxac capsules, Cosette is now listed in the Orange Book as the only approved provider of a liquid oral formulation, following approval through the 505(b)(2) pathway.
Generics Bulletin - October 27, 2026
Who’s Hired? Lupin Lifts Legal Leader From Teva
Lupin has looked to Teva to recruit its new chief legal officer. Meanwhile, Fresenius Kabi has a new biopharma business development lead; Centrient has named a new CFO; and Pharmanovia has appointed a new head of medical affairs.
Generics Bulletin - October 27, 2026
Lupin has looked to Teva to recruit its new chief legal officer. Meanwhile, Fresenius Kabi has a new biopharma business development lead; Centrient has named a new CFO; and Pharmanovia has appointed a new head of medical affairs.
Generics Bulletin - October 27, 2026
Is It Time To Phase Out ‘Women’s Health’?
‘Women’s health’ offers a distinct medical term for half the global population, but is it causing more harm than good? Some industry spectators believe the label has a shelf life.
In Vivo - October 27, 2026
‘Women’s health’ offers a distinct medical term for half the global population, but is it causing more harm than good? Some industry spectators believe the label has a shelf life.
In Vivo - October 27, 2026
Brainomix’s AI-Powered Precision Medicine Stroke Offering Targets Non-Specialist Centers
AI technology can directly address the unmet need whereby most sufferers of a stroke are not taken to a central stroke treatment hub but to a spoke site for their initial care. Brainomix CMO George Harston explained the problem and the solution at the annual CPI meeting in London in October.
In Vivo - October 27, 2026
AI technology can directly address the unmet need whereby most sufferers of a stroke are not taken to a central stroke treatment hub but to a spoke site for their initial care. Brainomix CMO George Harston explained the problem and the solution at the annual CPI meeting in London in October.
In Vivo - October 27, 2026
Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans
In this episode of Strategic Intent, David Evans, Partner at Sofinnova Partners, discusses his transition from Roche Venture Fund, different investment strategies, provides a general market analysis across Europe and US, and looks at growing therapeutic area trends within biotech.
In Vivo - October 27, 2026
In this episode of Strategic Intent, David Evans, Partner at Sofinnova Partners, discusses his transition from Roche Venture Fund, different investment strategies, provides a general market analysis across Europe and US, and looks at growing therapeutic area trends within biotech.
In Vivo - October 27, 2026